Brokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Price Target at $14.75

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have received a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $14.75.

DBVT has been the topic of several recent research reports. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, July 18th. Lifesci Capital raised shares of DBV Technologies to a “strong-buy” rating in a research note on Thursday, June 26th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Tuesday, May 27th. The Goldman Sachs Group raised shares of DBV Technologies to a “sell” rating and set a $7.25 price target for the company in a research note on Thursday, May 29th. Finally, JMP Securities reiterated a “market outperform” rating and set a $21.00 price target on shares of DBV Technologies in a report on Thursday, June 26th.

DBV Technologies Trading Down 0.6%

DBVT opened at $9.84 on Wednesday. The stock has a 50-day moving average of $9.69 and a 200 day moving average of $8.60. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $12.78. The firm has a market cap of $269.62 million, a P/E ratio of -2.06 and a beta of -0.36.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.34). The company had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. On average, research analysts forecast that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Vivo Capital LLC purchased a new position in DBV Technologies during the 2nd quarter valued at $9,659,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies in the second quarter worth $9,659,000. MPM Bioimpact LLC bought a new stake in shares of DBV Technologies during the second quarter worth $9,649,000. Octagon Capital Advisors LP purchased a new stake in shares of DBV Technologies during the second quarter valued at $9,315,000. Finally, Nan Fung Trinity HK Ltd. bought a new position in shares of DBV Technologies in the second quarter worth about $340,000. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.